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Objective To examine the risk of congenital abnormalities, preterm birth and low birth
weight after exposure to phenoxymethylpenicillin in utero.
Methods Apopulation-based follow-up study in the County of North Jutland, Denmark.
Birth outcome for 1886 women, who redeemed prescriptions for phenoxymethylpeni-
cillin during pregnancy was compared with the outcome for 9263 women who did not
redeem any prescription during pregnancy.
Results The prevalence of congenital abnormalities in 654 users of phenoxymethylpe-
nicillin with or without other drugs during the ﬁrst trimester was 4.6% compared with
3.6% in the reference group, giving a prevalence odds ratio of 1.25 (95%CI: 0.84–1.86). The
prevalence odds ratio was 1.35 (95% CI: 0.59–3.08) in 131 women who were exposed to
phenoxymethylpenicillin only. Nine cardiovascular abnormalities were found, giving an
adjusted prevalence odds ratio of 1.74 (95% CI: 0.83–3.65). The prevalence odds ratios of
preterm birth and low birth weight were 0.83 (95% CI: 0.66–1.04) and 1.02 (95% CI: 0.71–
1.47), respectively.
Conclusion We found no signiﬁcantly increased risk of congenital abnormalities, includ-
ing cardiovascular abnormalities, preterm birth, or low birth weight in women who
purchased phenoxymethylpenicillin during pregnancy.
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INTRODUCTION
Since the thalidomide disaster there has been
major concern about possible teratogenic effects
of drugs taken during pregnancy. Penicillins
account for approximately 20% of all prescriptions
ﬁlled by Danish women [1]. The pharmacokinetics
and distribution of penicillins in pregnant women
are well known, and penicillin crosses the placenta
[2–4]. Previous studies have not shown any
signiﬁcant association between maternal use of
penicillins of any kind during pregnancy and
the total number of congenital abnormalities. As
teratogens, however, do not uniformly increase the
risk of all congenital abnormalities, but rather of
speciﬁc abnormalities, the studies published so far
may not have been of sufﬁcient size to detect
associations between exposure to speciﬁc penicil-
lins and speciﬁc congenital abnormalities. It is
therefore important for all available data from
various studies to be published in a form that
permits pooling and meta-analyses [5].
Phenoxymethylpenicillin (penicillin V) remains
the drug of choice for a number of Gram-positive
bacterial infections and for prophylactic treatment
of carriers of group B b-hemolytic streptococci
during pregnancy [6], but data on this penicillin
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derivative with respect to safety during pregnancy
are few and inconsistent [7–11].
According to on apopulation-based cohort study
we report the association between maternal use
of penicillin V during pregnancy and congenital
abnormalities, preterm birth and low birth weight.
MATERIALS AND METHODS
Study population
We conducted the study in North Jutland County,
Denmark, which has approximately 490 000 in-
habitants, based on all primiparous women who
had a live single child or a stillbirth after the
28th gestational week (n¼ 35 950) for the period
1991–1998.
Exposure data
The North Jutland Pharmaco-Epidemiological
Prescription Database
The Danish National Health Service provides tax-
ﬁnanced 50% reimbursement of the costs of peni-
cillin V, which is purchased by prescription only.
The electronic accounting system, used primar-
ily to secure reimbursement from the Health Ser-
vice to the pharmacies, includes the type and
amount of the prescribed drug according to the
Anatomical Therapeutical Classiﬁcation Code
(ATC), the deﬁned daily dose, the date of issuing
the prescription, and the personal register number
of the patient (CPR number) which is assigned to
all citizens shortly after birth or at immigration,
encoding sex and date of birth.
All data are transferred to the research Prescrip-
tion Database, which retains key data on all pre-
scribed, reimbursed drugs sold at pharmacies in
the county since 1 January 1991. It is thus possible
to construct a complete prescription history for
each inhabitant in the county [12].
Outcome data
The Danish Medical Birth Registry
This registry contains information on all births in
Denmark since 1 January 1973, collected by mid-
wives and doctors attending the deliveries [13].
The main variables include maternal age, self-
reported smoking status, birth order, gestational
age, length and weight at birth, and CPR number
of both mother and child.
The County Hospital Discharge Registry
The County Hospital Discharge Registry was
established in 1977 and contains data on more
than 99% of the discharges from hospitals in the
county [14]. The main variables include the CPR
number of the patient, dates of admission and
discharge, surgical procedures, and up to 20 dis-
charge diagnoses, classiﬁed according to the 8th
revision of the Danish version of the International
Classiﬁcation of Diseases (ICD) until the end of
1993, and according to the 10th revision thereafter.
The registry was used to obtain information
about congenital abnormalities based on the diag-
noses 740–759 in ICD-8 and Q00-Q99 in ICD-10.
This registry has the advantage of accumulating
information about congenital abnormalities irre-
spective of the actual age of the patient at the time
of diagnosing the condition. All children recorded
in the registry until December 1998 were consid-
ered. We excluded the codes ‘dislocation of the
hip’ and ‘undescended testes’ (755.69 and 752.10–
752.19 in ICD 8, and Q53 and Q65 in ICD 10),
which we regard as invalid based on a previous
review of hospital records.
Linkage of data
All live births and stillborns after the 28th gesta-
tional week were identiﬁed in the Birth Registry,
and, based on the reported gestational age at birth,
we calculated the time of conception. The preg-
nancies were divided into period 1: the ﬁrst tri-
mester, and period 2: the second and third
trimesters. The pregnancies in which the women
had purchased a prescription for penicillin V (ATC
code J01C EO2) were further categorized accord-
ing to use of other medications in the periods,
hereafter referred to as ‘penicillin V only’ and
‘penicillin V and other drugs’.
During the study period, prescriptions for chil-
dren were identiﬁed and reimbursed according to
the mother’s CPR numbers. To avoid the potential
misclassiﬁcation resulting from antibiotics pre-
scribed for a child in the family, the analyses were
restricted to primiparous women.
Reference pregnancies
As a reference we selected all primiparous single-
ton pregnancies (n¼ 9263) in which the mothers
had purchased no prescription of any kind of
reimbursed medicine during pregnancy.
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Statistical analyses
We used logistic regression analyses to estimate
the prevalence odds ratios (POR) of congenital
abnormalities, preterm birth (gestational age
<37weeks), and low birth weight (<2500 g) asso-
ciated with penicillin V exposure, adjusted for
maternal age, birth order and smoking. Due to
the observation that 30% of congenital abnormal-
ities were cardiovascular, we made a separate
analysis of the risk association in these cases.
Pregnancies exposed in period one were used to
estimate the risk of congenital abnormalities, and
in periods one and two to estimate the risk of
preterm birth and low birth weight (the latter
analysis was restricted to full-term births). Regard-
ing the risk of congenital abnormalities, we made
separate analyses for ‘penicillin V only’ and ‘peni-
cillin V and other drugs’.
RESULTS
We identiﬁed 1886 pregnant women who pur-
chased at least one prescription for penicillin V
during pregnancy (Table 1). Apart from a higher
proportion of smokers among penicillin V and
other drug users, we found no signiﬁcant
differences regarding major characteristics be-
tween the cohorts.
Among 654 women exposed to penicillin V in
the ﬁrst trimester we found 4.6% (n¼ 30), com-
pared with 3.6% in the reference cohort, giving an
adjusted POR of 1.25 (95% CI: 0.84–1.86) (Table 2).
A review of the hospital records conﬁrmed all
congenital abnormalities identiﬁed from the reg-
istry (Table 3).
In the subgroup of 131 pregnancies exposed to
penicillin V only, the adjusted POR of congenital
abnormalities was 1.35 (95% CI: 0.59–3.08), and
for speciﬁc cardiovascular abnormalities (n¼ 9)
we found an adjusted POR of 1.74 (95% CI:
0.83–3.65).
The proportion of preterm birthswas 5.5% in the
users of penicillin V and 6.4% in the reference
group, giving an adjusted POR of 0.83 (95%
CI:0.66–1.04).
When restricted to full-term births, the POR
of low-birth-weight babies was 1.02 (95% CI:
0.71–1.47).
DISCUSSION
We did not ﬁnd any signiﬁcant risk of congenital
abnormalities, preterm birth, or low birth weight
Table 1 Characteristics of the study cohort of pregnant women filling prescriptions for penicillin V during pregnancy, and
the reference cohort
Variable
Exposed during
first trimester
Exposed at any time
during pregnancy Reference cohorta
No. of women 654 1886 9263
No. of prescriptions 700 2272 –
Maternal age (years)
Mean 25.9 26.1 26.7
Range 16–39 16–44 13–45
Proportion of smokers 35.6% 34.7% 28.4%
Gestational age at birth
>37 weeks (n) 601 1783 867
34–36 weeks (n) 37 76 416
<34 weeks (n) 16 27 177
Birth weight (g)
Mean 3395 3439 3417
Range, grams 850–5220 846–5340 630–5520
No. of babies with congenital abnormalities 30 69 332
No. of low-birth-weight infants 35 (9)b 88 (37)b 503 (171)b
No. of preterm births 53 103 593
No. of stillborns (before birth) 3 5 29
No. of stillborns (during birth) 1 1 7
aReference cohort was not exposed to any drugs.
bThe number of full-term births is given in parentheses.
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in women who had purchased penicillin V during
pregnancy.
Our population-based design has advantages
and limitations. Data have proved highly reliable
in both the Prescription Database [15] and the
Danish Medical Birth Registry [16], thus prevent-
ing several types of bias.Wewere able to adjust for
gestational age, as well as prescribed, reimbursed
co-medication. Outcome data were obtained inde-
pendently of exposure information,whichprevents
the recall bias that often hampers case–control
studies based on postpartum interviews [5].
Our deﬁnition of exposure relies exclusively on
the assumption that prescribedmedicine had actu-
ally been used shortly after purchase which may
not have been the case, and additionally, we have
no information about actual compliance. Since
penicillin V in this cohort has most often been
prescribed to prevent adverse effects on the fetus
(group B b-hemolytic streptococci) we would
expect the pregnant women to have a fairly good
compliance. Moreover, themedicine has been paid
for in part by the women, which may also lead to a
better compliance than in studies merely based on
prescriptions handed out without change from the
doctor’s ofﬁce. Another limitation of our study is
the lack of information about spontaneous mis-
carriages and abnormal fetuses detected at prena-
tal screening and consequently aborted.
No teratogen will uniformly increase the risk of
all abnormalities. Very large study groups will
therefore be required to asess the risk of speciﬁc
congenital abnormalities. Our relatively large
cohort comprising 654 women exposed in the ﬁrst
trimester had insufﬁcient power to detect even a
moderate increase in a speciﬁc congenital abnorm-
ality. We could only exclude a 90% increased risk
in overall congenital abnormalities.
To secure optimal use of data from smaller
studies it is therefore important, that all studies
report data in a way that permits subsequent
pooling and meta-analysis of available data.
Our results are consistent with the few pub-
lished studies adressing this topic. In a case–con-
trol study, Czeizel et al. [7] found that 0.8% of
womenwho had a child with a congenital abnorm-
ality had been treated with penicillin V during
pregnancy, compared with 0.6% in a reference
cohort, giving a POR of 1.3 (95% CI: 1.1–1.6). This
difference, however, was ascribed to recall bias or
undetected confounding. In cohort studies based
on prescription databases, Jick et al. [8] andT
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Aselton et al. [9] did not ﬁnd any increased risk in
349 and 297 exposed pregnancies, respectively.
Based on a series of 4597 newborns from the
Michigan Medicaid surveillance study no associa-
tion was found between penicillin V and adverse
pregnancy outcome [17]. Heinonen et al. did not
ﬁnd any association between exposure to various
penicillin derivatives during the ﬁrst four lunar
months in 3546 pregnancies and broad classes of
congenital abnormalities [10].
In conclusion, our study did not indicate that
intrauterine exposure to penicillin V is associated
with any major additional risk to the fetus of
congenital abnormalities, preterm birth, or low
birth weight.
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